1. Editor's page

   EditorialNotes Pages: S - S

2. Introduction to toremifene

   • Lauri Kangas

   Symposium lectures and reports Pages: S - S

3. Preclinical studies with toremifene as an antitumor agent

   • Simon P. Robinson
   • Christopher J. Parker
   • V. Craig Jordan

   Symposium lectures and reports Pages: S - S

4. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer

   • Peter C. Kohler
   • John T. Hamm
   • Douglass C. Tormey

   Symposium lectures and reports Pages: S - S

5. A phase I study of toremifene

   • Takeshi Tominaga
   • Osahiko Abe
   • Yasuo Nomura

   Symposium lectures and reports Pages: S - S

6. Phase II trials with toremifene in advanced breast cancer: A review

   • Ritva Valavaara

   Symposium lectures and reports Pages: S - S

7. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer an ongoing phase II multicenter Finnish-Latvian cooperative study

   • Tenho Hietanen
   • Dace Baltina
   • Ritva Valavaara

   Symposium lectures and reports Pages: S - S

8. Phase III studies of toremifene in metastatic breast cancer

   • Seppo O. Pyrhönen

   Symposium lectures and reports Pages: S - S

9. Toremifene — panel discussion and summary

   • C. Kent Osborne

   Discussion Pages: S - S